Yasemin Baranoglu Kilinc

Yasemin Baranoglu Kilinc

Auto-generated profile, based on publicly available information

Yasemin Baranoglu Kilinc

Department of Pediatrics Gaziosmanpasa SUAM, University of Health Sciences İstanbul Türkiye

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
ITIbrahim Ethem Torun
Ibrahim Ethem Torun
YKYasemin Baranoglu Kılınc
Yasemin Baranoglu Kılınc
EKErkan Kilinc
Erkan Kilinc
Background: Epilepsy has neuropsychiatric comorbidities such as depression, bipolar disorder, and anxiety. Drugs that target epilepsy may also be useful for its neuropsychiatric comorbidities. Objective: To investigate the effects of serotonergic modulation on pro-inflammatory cytokines and the seizures in pentylenetetrazole (PTZ)-induced seizure model in rats. Methods: Male Wistar rats were injected intraperitoneally with serotonin, selective serotonin reuptake inhibitor fluoxetine, 5-HT1B/D receptor agonist sumatriptan, or saline 30 min prior to PTZ treatment. Behavioral seizures were assessed by the Racine's scale. Concentrations of IL-1β, IL-6, and TNF-α in serum and brain tissue were determined by ELISA. Results: Serotonin and fluoxetine, but not sumatriptan, alleviated PTZ-induced seizures by prolonging onset times of myoclonic-jerk and generalized tonic-clonic seizures. The anti-seizure effect of fluoxetine was greater than that of serotonin. Likewise, serotonin and fluoxetine, but not sumatriptan, reduced PTZ-induced increases in the levels of IL-1β and IL-6 in both serum and brain tissue. None of the administered drugs including PTZ affected TNF-α concentrations. Conclusions: Our findings suggest that endogenous and exogenous serotonin exhibits anticonvulsant effects by suppressing the neuroinflammation. It seems that 5-HT1B/D receptors do not mediate anticonvulsant and anti-neuroinflammatory effects of serotonin.

20 March 2020 in Anadolu Kliniği Tıp Bilimleri Dergisi
Verified
Journal Article
Open access
EKErkan Kilinç
Erkan Kilinç
YBYasemin Baranoğlu
Yasemin Baranoğlu
SARS-CoV-2(COVID-19) leads to severe acute respiratory syndrome by settling the pulmonary system. Mast cells (MCs) are multifunctional immune cells that are extensively distributed throughout the body and mostly present in pulmonary system. MCs play a vital role in acquired and innate immunity, and to maintain immune homeostasis of the body through a wide range of mediators in their cytoplasmic granules. Severe acute respiratory syndrome with proinflammatory cytokine release and pneumonia during COVID-19 infection can result in the death, in particular in debilitated individuals or those suffering from related chronic disorders. In this review, we attempt to discuss potential relationship between COVID-19 symptoms and mast cells as well as potential use of mast cell stabilizers as a supportive therapeutic option in COVID-19 infection. MCs are main source of pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α as well as bronchoconstrictor mediators such as histamine, prostaglandin-D2 and leukotriene-C4 that can lead to fatal inflammatory responses and pulmonary complications during COVID-19 infection. SARS-CoV-2 may activate MCs through toll-like receptors or by inducing the cross-linking of the IgE-FcεRI, thus leading to release of those mediators. SARS-CoV-2-induced abnormal production and release of these mediators from MCs can further exacerbate inflammation in respiratory system, consequently pulmonary complications.Therefore administration of MC stabilizers as a supportive therapy may be useful to alleviate inflammatory responses and pulmonary complications in order to reduce deaths from SARS-CoV-2 infection.

15 March 2023 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
YKYasemin Baranoglu Kilinc
Yasemin Baranoglu Kilinc
MDMustafa Dilek
Mustafa Dilek
EKErkan Kilinc
Erkan Kilinc
ITIbrahim Ethem Torun
Ibrahim Ethem Torun
ASAslihan Saylan
Aslihan Saylan
SDSelma Erdogan Duzcu
Selma Erdogan Duzcu

6 January 2024 in European Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
MBMervan Bekdas
Mervan Bekdas
BSBilgi Saygi
Bilgi Saygi
YKYasemin Baranoglu Kilinc
Yasemin Baranoglu Kilinc
EKErkan Kilinc
Erkan Kilinc
Neurogenic inflammation is involved in the development and progression of respiratory inflammatory diseases. However, its role in community-acquired pneumonia (CAP) remains unclear. We therefore aimed to investigate plasma levels of neurogenic inflammation-related neuropeptides, calcitonin gene-related peptide (CGRP), substance P (SP), vasoactive intestinal peptide (VIP) and neuropeptide Y (NPY), and procalcitonin (PCT) in pediatric patients with CAP and to assess their diagnostic value in viral and bacterial/mixed pneumonia. A total of 124 pediatric patients with CAP (1 month-18 years old) and 56 healthy children of similar ages were prospectively enrolled. The patients were classified as viral (n = 99) and bacterial/mixed (n = 25) pneumonia. Plasma levels of the peptides were quantified by ELISA. ROC analysis was performed to evaluate possible diagnostic value of the peptides. While plasma levels of CGRP, VIP and PCT were significantly higher in patients with CAP than in the control group, respectively, NPY levels were significantly lower. Moreover, plasma levels of all neuropeptides and PCT were significantly higher in bacterial pneumonia patients compared to viral pneumonia patients. ROC analysis revealed that CGRP, SP and NPY had a diagnostic value in distinguishing viral and bacterial/mixed pneumonia.Conclusions: Our findings suggest that these neuropeptides may be implicated in pediatric CAP. CGRP, SP and NPY together may be a promising candidate in distinguishing viral and bacterial/mixed pneumonia, however, for this, further studies are needed. What is Known:• Neurogenic inflammation contributes to the development and progression of respiratory inflammatory diseases such as chronic obstructive pulmonary disease and bronchial asthma. What is New:• Plasma levels of neurogenic inflammation related neuropeptides calcitonin gene-related peptide, substance P, vasoactive intestinal peptide and neuropeptide Y are changed in pediatric community-acquired pneumonia. Calcitonin gene-related peptide, substance P and neuropeptide Y are promising candidates in distinguishing viral and bacterial/mixed pneumonia.